{
    "2018-01-23": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Key Updates on Novartis’s Kymriah",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kymriah",
                        "Updates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Analysts More Bullish On Celgene-Juno, But Sales Outlook Nags",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Juno",
                        "Bullish",
                        "Sales Outlook"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Announces Positive Results on Migraine Candidate",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Positive Results",
                        "Migraine"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "VTVT Up 30% In 5 Days, INO Gets Shot In The Arm, DRNA, HBIO On Fire",
                "features": {
                    "keywords": [
                        "VTVT",
                        "INO",
                        "DRNA",
                        "HBIO",
                        "Up"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-24",
                "original_text": "Pre-Market Earnings Report for January 24, 2018: CMCSA, GE, UTX, ABT, GD, ITW, NSC, TEL, PGR, NVS, APH, RCL",
                "features": {
                    "keywords": [
                        "Earnings",
                        "CMCSA",
                        "GE",
                        "UTX",
                        "ABT",
                        "GD",
                        "ITW",
                        "NSC",
                        "TEL",
                        "PGR",
                        "NVS",
                        "APH",
                        "RCL"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diverse"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Pharma and Biotech Stocks to Watch Out for in 2018",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Biotech",
                        "Stocks",
                        "Watch"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "How Is Novartis’s Kymriah Positioned for 2018?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kymriah",
                        "Positioned"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Migraine",
                        "Drug",
                        "Phase IIIb"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis on the Street: Analyst Ratings and Recommendations",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Analyst Ratings",
                        "Recommendations"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Celgene, Novartis Both Report Billion Dollar Buyouts",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Novartis",
                        "Buyouts"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Top 5 Johnson & Johnson Shareholders (JNJ)",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Shareholders",
                        "JNJ"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies",
                "features": {
                    "keywords": [
                        "Teva",
                        "Reslizumab",
                        "Fails",
                        "Late-Stage"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Why Celgene's Acquisition Of Juno Matters For Biotech And Investors",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Juno",
                        "Acquisition",
                        "Biotech",
                        "Investors"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Reading the Estimates for Novartis’s Alcon in 4Q17",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Alcon",
                        "Estimates",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "What’s Expected of Novartis’s Sandoz Segment in 4Q17?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "Expected",
                        "4Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Swiss Stock Market Climbed On Strength Of Index Heavyweights",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Climbed",
                        "Index Heavyweights"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Teva Pharmaceutical Industries Ltd -- Moody's: European generic drug market growth to continue into 2020 on patent expiries, rising usage",
                "features": {
                    "keywords": [
                        "Teva",
                        "Moody's",
                        "Generic Drug",
                        "Market Growth",
                        "Patent Expiries"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}